Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 10/21 05:31:37 pm
74.9 CHF   -0.40%
10/20 NOVARTIS : The American Heart Association and Novartis Shine a Light..
10/20 Positive Phase III Clinical Trial Results for Ribociclib (LEE011)..
10/20 CERULEAN PHARMA : CERU) Files An 8-K
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
10/20 NOVARTIS : Researchers Submit Patent Application, "2'-Branched Nucleosides for T..
10/20 NOVARTIS : breakthrough therapy LEE011 ribociclib plus letrozole demonstrates su..
10/20 NOVARTIS : The American Heart Association and Novartis Shine a Light on America'..
10/20 Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investi..
10/19 CERULEAN PHARMA : CERU) Higher on $20M Purchase Agreement with Aspire Capital, A..
10/19 NOVARTIS : Kala azar the bane of West Pokot  
10/18 NOVARTIS : Alcon launches the CyPass Micro-Stent at the American Academy of Opht..
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17 NOVARTIS : Alcon launches the CyPass® Micro-Stent at the American Academy of Oph..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 BIOTECH FORUM DAILY DIGEST : Biotech Slowly Recovering, Analysts Line Up Behind ..
10/21 OMEROS : Upside/Risk With Orphan Drug Strategy
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
10/19 Pfizer Takes Risk For Biosimilar Followers
10/19 Cerulean inks collaboration with Novartis and nabs $20M equity investment at ..
Financials ($)
Sales 2016 48 968 M
EBIT 2016 11 647 M
Net income 2016 7 920 M
Debt 2016 14 564 M
Yield 2016 3,77%
P/E ratio 2016 22,24
P/E ratio 2017 20,36
EV / Sales 2016 4,35x
EV / Sales 2017 4,23x
Capitalization 198 298 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,1 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-13.36%198 298
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results